Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network
Open Access
- 1 January 2024
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 16
Abstract
Background: Cancer-related fatigue (CRF) occurs in nearly all patients with metastatic breast cancer (MBC). Objectives: This real-world analysis aimed to describe the prevalence and importance of fatigue in patients with MBC within 3 months of treatment with single-agent taxane-based chemotherapy during the timeframe of 2020–2022 in the United States and Europe. It was also conducted to assess whether there was a difference in relapsed patients compared to patients diagnosed de novo. Design: Electronic health records were analyzed from approximately 150 million patients to identify patients with MBC who underwent taxane treatment. Results: In 2021, 50,490 patients had MBC, of whom 16,170 were diagnosed de novo and 34,330 experienced relapse. The proportion of patients undergoing taxane-based chemotherapy was 7.5% ( n = 1220) and 13.4% ( n = 4590), respectively, and the prevalence of any fatigue and CRF was similar between the groups (24.6% versus 25.7% and 6.6% versus 5.4%, respectively). Conclusion: At least one in four patients with MBC undergoing taxane-based treatment will experience fatigue. This highlights the importance of validating screening tools to identify CRF, which is necessary to advance clinical trials aimed at investigating treatment strategies to improve patient-centered outcomes for fatigue.Keywords
Funding Information
- Dompé farmaceutici S.p.A.
This publication has 18 references indexed in Scilit:
- Cytokine-associated fatigue prior to, during, and post-chemotherapy for breast cancerJournal of Neuroimmunology, 2019
- Long-Term Side Effects of Adjuvant Therapy in Primary Breast Cancer Patients: Results of a Web-Based SurveyBreast Care, 2019
- Symptoms Experience and Quality of Life in The Patients With Breast Cancer Receiving The Taxane Class of DrugsEuropean Journal of Breast Health, 2018
- The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?The Breast, 2017
- Cancer-related fatigue—mechanisms, risk factors, and treatmentsNature Reviews Clinical Oncology, 2014
- Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: A randomized phase-II study of the Belgian Society of Medical OncologyCritical Reviews in Oncology/Hematology, 2010
- Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patientsBreast Cancer Research and Treatment, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002
- Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue CoalitionThe Oncologist, 2000